Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug

Drug Discovery Today

Volumn 13, Issue 21-22, 2008, Pages 1002-1009

  Fiume, Luigi ^a   Baglioni, Michele ^a   Bolondi, Luigi ^a   Farina, Claudio ^b   Di Stefano, Giuseppina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Kedrion Biopharmaceuticals ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN CONJUGATE; ASIALOGLYCOPROTEIN RECEPTOR; DOXORUBICIN; DOXORUBICIN LACTOSAMINATED HUMAN ALBUMIN CONJUGATE; HUMAN ALBUMIN; LACTOSE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; DRUG ABSORPTION; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; REVIEW; SYSTEMIC THERAPY;

ALBUMINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; DRUG CARRIERS; LACTOSE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS, EXPERIMENTAL; RATS;

EID: 54249085764     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.07.009     Document Type: Review

References (45)

1. Llovet J.M., et al. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Schneider Y., et al. Drug targeting in human cancer chemotherapy. In: Gregoriadis G., et al. (Ed). Receptor-mediated Targeting of Drugs, NATO ASI Series A: Life Sciences. Vol. 82 (1984), Plenum Press 1-25
3. O'Hare K.B., et al. Effect of galactose on interaction of N-(2-hydroxypropyl) metacrylamide copolymers with hepatoma cells in culture: preliminary applications to an anticancer agents, daunomycin. Hepatology 10 (1989) 207-214
4. 3H]thymidine incorporation into DNA of rat regenerating liver by 2′,2′-difluorodeoxycytidine coupled to lactosaminated poly-l-lysine. Biochem. Pharmacol. 57 (1999) 793-799
5. Morell A.G., et al. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J. Biol. Chem. 243 (1968) 155-159
6. Ashwell G., and Harford J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51 (1982) 531-534
7. Fiume L., et al. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett. 103 (1979) 47-51
8. Fiume L., et al. Hepatocyte targeting of adenine-9-β-d-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett. 129 (1981) 261-264
9. Trerè D., et al. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br. J. Cancer 81 (1999) 404-408
10. Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J. Biol. Chem. 253 (1978) 2070-2072
11. Torrani Cerenzia M.R., et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin, administered for 4 weeks to patients with chronic type B hepatitis, decreased viremia without producing significant side effects. Hepatology 23 (1996) 657-661
12. Zarski J.P., et al. Efficacy and safety of L-HSA-ara-AMP in chronic hepatitis B patients non responder to interferon therapy: a randomised clinical trial. J. Hepatol. 34 (2001) 487-488
13. Di Stefano G., et al. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas, independently of their differentiation grade. Liver Int. 26 (2006) 726-733
14. Di Stefano G., et al. Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. Liver Int. 25 (2005) 854-860
15. Schwartz B.A., and Gray G.R. Proteins containing reductively aminated saccharides. Synthesis and chemical characterization. Arch. Biochem. Biophys. 181 (1977) 542-549
16. Willner D., et al. (6-Maleimidocaproyl)hydrazone derivative of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 4 (1993) 521-527
17. Greenfield R.S., et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 50 (1990) 6600-6607
18. Etrych T., et al. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 73 (2001) 89-102
19. Di Stefano G., et al. Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. Eur. J. Pharm. Sci. 33 (2008) 191-198
20. Le Sann C. Maleimide spacers as versatile linkers in the synthesis of bioconjugates of anthracyclines. Nat. Prod. Rep. 23 (2006) 357-367
21. Drevs J., et al. Phase I dose-escalation and pharmacokinetic (PK) study of a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers. J. Clin. Oncol. 22 14S (2004) 2125
22. Seymour L.W., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668-1676
23. Hovorka O., et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J. Control. Release 80 (2002) 101-117
24. Di Stefano G., et al. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur. J. Pharm. Sci. 23 (2004) 393-397
25. Rajewsky M.F., et al. Liver carcinogenesis by diethylnitrosamine in the rat. Science 152 (1966) 83-85
26. Freireich E.J., et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50 (1966) 219-244
27. Baglioni M., et al. Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. Dig. Liver Dis. (2008) 10.1016/j.dld.2008.05.014
28. Goomaghtigh E., et al. Evidence of a specific complex between adriamycin and negatively charged phospholipids. Biochim. Biophys. Acta 597 (1980) 1-14
29. Miyamoto Y., et al. Comparison of the cytotoxic effect of the high- and low-molecular-weight anticancer agents on multidrug-resistance Chinese hamster ovary cells in vitro. Cancer Res. 50 (1990) 1571-1575
30. Fiume L., et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J. Hepatol. 43 (2005) 645-652
31. Fiume L., et al. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat. Cancer Drug Deliv. 4 (1987) 145-150
32. Di Stefano G., et al. Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. Dig. Liver Dis. 38 (2006) 404-408
33. Di Stefano G., et al. Liver targeted doxorubicin: effects on regenerating rat hepatocytes. Liver Int. 24 (2004) 246-252
34. Di Stefano G., et al. Efficacy of doxorubicin coupled to lactosaminated albumin on rat HCCs evaluated by ultrasound imaging. Dig. Liver Dis. 40 (2008) 278-284
35. Mazuè G., et al. Anthracyclines: a review of general and special toxicity studies. Int. J. Oncol. 7 (1995) 713-726
36. Di Stefano G., et al. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin. Eur. J. Pharm. Sci. 30 (2007) 136-142
37. Graham K.C., et al. Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res. 65 (2005) 5231-5237
38. Fukumura D., et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am. J. Pathol. 151 (1997) 679-688
39. Seymour L.W. Soluble polymers for lectin-mediate drug targeting. Adv. Drug Deliv. 14 (1994) 11-89
40. Gabizon A., and Martin F. Polyethylene glycol-coated (pegylated) lyposomal doxorubicin. Rationale for use in solid tumors. Drugs 54 (1997) 15-21
41. Hilmer S.N., et al. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab. Dispos. 32 (2004) 794-799
42. Hong R.L., and Tseng Y.L. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 51 (2003) 433-438
43. Barraud L., et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42 (2005) 736-743
44. Gibaud S., et al. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer 30A (1994) 820-826
45. Simpson D., and Keating G.M. Sorafenib in hepatocellular carcinoma. Drugs 68 (2008) 251-258